In 1995, BIBP introduced the Recombinant Hepatitis B Vaccine (Saccharomyces cerevisiae) (rHBV) technology from Merck, and obtained the marketing approval for rHBV. It is produced by hepatitis B virus surface antigen (HBsAg) expressing in Saccharomyces cerevisiae. The culture is purified by cell breakage, cell debris removal, small molecules removal, gel adsorption, boric acid elution, ultrafiltration, concentration and hydrophobic chromatography, and then perform the in-situ adsorption, and dilute by adding aluminum adjuvant to prepare the vaccine. It is semi-transparent suspension which displays a slightly white to off-white color after shaking, could be layered by precipitation, and the precipitation can be easily dispersed by shaking. It is free of preservatives, and can be used for prevention of hepatitis B.